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Copenhagen, Denmark; Montreal, Quebec, Canada; Bonn, Germany; Kyoto, Japan; and Rotterdam, The NetherlandsAtopic dermatitis (AD) is a common yet complex skin disease,
posing a therapeutic challenge with increasingly recognized
different phenotypes among variable patient populations.
Because therapeutic response may vary on the basis of
heterogeneous clinical and molecular phenotypes, a shift toward
precision medicine approaches may improve AD management.
Herein, we will consider biomarkers as potential instruments in
the toolbox of precision medicine in AD and will review the
process of biomarker development and validation, the opinion
of AD experts on the use of biomarkers, types of biomarkers,
encompassing biomarkers that may improve AD diagnosis,
biomarkers reflecting disease severity, and those potentially
predicting AD development, concomitant atopic diseases, or
therapeutic response, and current practice of biomarkers in AD.
We found that chemokine C-C motif ligand 17/thymus and
activation-regulated chemokine, a chemoattractant of TH2 cells,
has currently the greatest evidence for robust correlation with
AD clinical severity, at both baseline and during therapy, by
using the recommendations, assessment, development, and
evaluation approach. Although the potential of biomarkers in
AD is yet to be fully elucidated, due to the complexity of the
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Atopic dermatitis (AD) is a complex disorder in which gene-
gene and gene-environment interactions contribute to generate a
highly heterogeneous clinical phenotype.1 This heterogeneity
likely reflects yet-to-be-defined mechanisms, coupled with clin-
ical relevance we are only beginning to grasp. Progress in our un-
derstanding of the role ofmicrobiome, epidermal barrier function,
and different cytokines and other immune mediators underlying
the chronic AD inflammation has led to an unprecedented number
of new compounds in clinical development, for both the topical
and systemic therapy of AD.2 However, thus far none of the ther-
apeutic approaches can be considered a magic bullet, or a ‘‘one-
size-fits-all’’ agent. When using stringent end points such as
percent of patients reaching investigator’s global assessment 0/
1 with a 2-grade decrease or Eczema Area and Severity Index-
90 in a monotherapy study design (ie, without adding topical/sys-
temic anti-inflammatory medications), it appears that both bio-
logics that specifically target cytokines or their receptors and
broad-acting Janus kinase inhibitors fail to fully control AD in
most patients.3-6 Hence, particularly considering the complexity
of AD, there is a need to shift toward precision medicine ap-
proaches to improve AD management.BIOMARKERS: DEFINITION, SUBTYPES, AND
OTHER REGULATORY ASPECTS
Biomarkers have always existed for different purposes in
medicine, principally as a diagnostic tool. However, AD diag-
nosis and treatment, as opposed to many other chronic diseases,
relies completely on clinical scores rather than biochemical
markers. Thus, a reliable biomarker will reduce observatory
differences. Herein, we will consider biomarkers as potential
instruments in the toolbox of precision medicine in AD. Bio-
markers may have tremendous implications in prevention strate-
gies and, most importantly, in strategies used for the development
of upcoming new compounds on the background of stringent
regulatory landscapes. In this regard, the definition of a biomarker
given by regulatory organizations is particularly helpful but
obviously not universal. The Food and Drug Administration
(FDA) has adopted a rather broad definition: ‘‘A defined
characteristic that is measured as an indicator of normal biologic
processes, pathogenic processes, or responses to an exposure or1
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and EvaluationIEC: International Eczema CouncilMDC: Macrophage-derived chemokineTARC: Thymus and activation-regulated chemokineintervention, including therapeutic interventions.’’ The FDA also
adds the following comment: ‘‘Molecular, histologic, radio-
graphic, or physiologic characteristics are types of biomarkers.
A biomarker is not an assessment of how an individual feels,
functions, or survives.’’ Interestingly, the European Medicines
Agency has another, more restrictive definition: ‘‘A biological
molecule found in blood, other body fluids, or tissues that can be
used to follow body processes and diseases in humans and
animals.’’
In the process of biomarker discovery, one should distinguish
between the kind of biologic material (or its origin) on one hand
and the purpose/value of the biomarker on the other hand. For the
first group, a wide range of biologic material can be used such as
(1) genomic information (eg, specific gene sequences or epige-
netic modification of genes), (2) transcriptomic profiles obtained
by analysis of mRNA and miRNA, (3) proteins such as cytokines
and other mediators from body fluids (whole blood, serum,
plasma, tissue fluids) or tape stripping, and (4) morphological
information (immunohistochemical staining and pictures
thereof).
This is to be distinguished from the purpose/value of biomarkers
with 7 different subtypes as defined by the FDA-NIH Biomarker
WorkingGroup (www.ncbi.nlm.nih.gov/books/NBK326791/): (1)
susceptibility/risk, (2) diagnostic, (3) monitoring/severity, (4)
prognostic, (5) predictive, (6) pharmacodynamic/response, and
(7) safety. All these subtypes could potentially be of importance
in the context of the management of AD.
Unfortunately, the literature and the classical understanding
thereof in the scientific community has generated the idea that a
biomarker can be easily described and used in the context of
disease management. In reality, bringing a given biomarker from
discovery to clinical practice and regulatory acceptance in clinical
development and/or as a companion diagnostic is a rather
complex procedure, widely underestimated by most scientists,
which is often comparable to a drug development process. There
are several crucial steps in the evolution of a biomarker before it
reaches the status of qualification in clinical practice.
In a nutshell, the life of a biomarker starts with its discovery,
which can be either by chance or the product of a hypothesis-
driven biomarker discovery program based on a patient registry
collecting high-quality phenotypical data linked to a biobankwith
several hundreds of specimens from these patients. The next step
is a first (internal) analytical and clinical validation in a limited
number of clinical cases. Thereafter, the biomarker must undergo
another (external) validation step, ideally from independent
institutions, using a large cohort of patients where the reproduc-
ibility is key. Once this goal of internal and external validation isreached, the biomarker is subjected to a complex process of
regulatory qualification, which is supported by a number of
guidance documents from the regulatory agencies (FDA, Euro-
pean Medicines Agency). Thus, developing a newly discovered
biomarker to the stage of an accepted companion diagnostic for
the management of a disease is a complex and demanding
process.THE GRADING OF RECOMMENDATIONS,
ASSESSMENT, DEVELOPMENT, AND
EVALUATION APPROACH TO ASSESS EVIDENCE
STRENGTH
TheGrading of Recommendations, Assessment, Development,
and Evaluation (GRADE) approach offers a system for rating
quality of evidence, with a structured process for developing and
presenting evidence summary.7 Herein, we searched for AD-
related publications that included correlation analysis and found
a significant (P < .05) correlation coefficient of greater than or
equal to 0.4 between AD clinical severity and blood/skin potential
biomarkers, both at baseline and during various AD treatments,
and across both pediatric and adult patients. Biomarkers that
were found to robustly correlate with AD clinical severity in
more than 3 publications were included in this review. Next, we
summarized these findings using the GRADE approach, in which
accumulated evidence per each potential biomarker (separated by
pediatric and adults, and at baseline and during topical and sys-
temic treatments) was graded on the basis of strength of the over-
all published data, given our inclusion threshold.BIOMARKERS IN AD INTERNATIONAL ECZEMA
COUNCIL SURVEY RESULTS
The International Eczema Council (IEC) consists of more than
100 councilors and associates (https://www.eczemacouncil.org/),
all experts in AD. Before the IECmeeting at the Society of Inves-
tigative Dermatologymeeting in 2019 in Chicago, an invitation to
an internet-based survey on biomarkers for AD was sent by email
to all IEC councilors and associates to examine their opinion
regarding biomarkers in AD (Table I; for detailed questions, see
this article’s Online Repository at www.jacionline.org). Monkey
survey software was used for data collection. Overall, the experts
believe AD is a heterogeneous disease with at least 3 different
phenotypes, that biomarkers may help to stratify patients by phe-
notypes and improve patient management and treatment compli-
ance, and that future developments should focus on their use as
predictors of therapeutic response.TYPES OF BIOMARKERS IN AD
Potential biomarkers may be subdivided on the basis of their
suggested use.Biomarkers differentiating AD from psoriasis
Some biomarkers seem to reliably distinguish between AD and
psoriasis (namely NOS2 and chemokine C-C motif ligand [CCL]
27/cutaneous T-cell–attracting chemokine [CTACK]),8-10 thus
potentially improving the diagnosis and management of patients
with psoriasiform dermatitis (Table II).
TABLE I. Results of the biomarkers survey by IEC AD experts
Question Yes (N) No (N) Follow-up questions (N)
Do you think that AD is a
heterogeneous disease?
97.52% (41) 2.38% (1) How many different AD phenotypes are there? (38)
d >3 types of different AD phenotypes (92.7%)
d <3 (7.3%)
How would you stratify AD phenotypes? (38)
d Combining clinical features and biomarkers (92.7%)
d Only clinical features (7.3%)
Which groups of biomarkers should be used for patients’ stratification? (36)
d Blood biomarkers (70%)
d Skin biomarkers (genomics/transcriptomics) (50%)
d Proteomics (28%)
d Genomics and transcriptomics in tape-strips (28%)
d Physiological properties (eg, TEWL and Raman spectroscopy) (25%)
Are you using blood tests/biomarkers
for the diagnosis of AD?
29.55% (13) 70.45% (31) Which are you using? (13)
d IgE (100%)
d Eosinophils (92.3%)
d Other (FLG, LDH, CCL17/TARC) (30.8%)
Do you think that blood tests/biomarkers
are useful for assessing the severity of AD?
59.09% (25) 40.91% (18) Why not?
d Lack of reliability, validity, and commercial availability
Why yes?
d Improve selection of patients for specific therapies or in clinical trials
d Improve comparability of clinical trials
d Allow better follow-up tool in daily practice
d Improve compliance of patients and patient encouragement.
Could blood test/biomarkers be useful for
assessing treatment compliance?
76.74% (33) 23.26% (10) Which biomarkers would you suggest? (17)
d CCL17/TARC (52.9%)
d IgE (47.1%)
d p-EASI (formula containing CCL17/TARC, sIL-2R, IL-22) (35.3%)
d Eosinophils (35.3%)
d IL-13 (23.5%)
d Other markers (CCL22, CCL26, sIL-2R, and IL-22—selected by <23.5%)
How would you prioritize the needs for
blood test/biomarkers?
Top-rated development priorities: (40)
d Biomarkers predicting treatment response, either in general, by identification of AD endo/phenotypes to
predict treatment response, or by identifying responders to a particular drug before treatment initiation
Lower priority for development:
d The use of biomarkers for disease severity, treatment response, diagnosis, and the development of less-
invasive biomarkers (all ranked almost equally)
EASI, Eczema Area and Severity Index; LDH, lactate dehydrogenase; TEWL, transepidermal water loss.
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These include markers related with general inflammation such
as serum lactate dehydrogenase,11-14 C-reactive protein,11 along
with markers related with allergy (eg, peripheral eosinophil
counts).11,12,15-19 Because AD is TH2/TH22-centered, cytokines
and chemokines related with these immune pathways and
correlated with disease severity in untreated or posttreated
tissues (either skin or serum) were also investigated as
possible biomarkers (Tables III and IV and Fig 1). Such
cytokines include the key TH2 marker IL-13
41,58,59,66,67,95,100
and the key TH22-related cytokine IL-22.
41,58,59,64,84 TH2-
related chemokines correlated with AD severity include
CCL17/thymus and activation-regulated chemokine
(TARC),13,14,20,24,27-33,35-39,94,101-104 CCL26/eosinophil-
attracting chemokine (eotaxin-3),43,58,68,85,91,95,105 CCL27/
CTACK,29,30,33,74,75 CCL18/pulmonary and activation-regulated
chemokine,65,68,83,84 and CCL22/macrophage-derived chemo-
kine (MDC).26,28,40,44,45,90 Of note, circulating AD-related bio-
markers are found in moderate to severe patients, whereas mild
patients may not consistently display upregulation of AD-
related biomarkers in their serum.25Barrier-related potential biomarkers, including filaggrin
(FLG), loricrin, and natural moisturizing factor, may inversely
correlate with disease severity.106
Because of the complexity of AD pathogenesis, a few reports
modeled a combination of biomarkers to better reflect molecular
changes correlating with clinical severity.39,58,107 The current ev-
idence from the literature, including only those reports in which a
significant and robust correlation between AD clinical severity
and a tissue biomarker was found (r >_ 0.4; P <.05), is summarized
using the GRADE approach in Table V.7Biomarkers that failed to show consistent
correlation with severity
Although total serum IgE levels (particularly in extrinsic
AD)11,13,28,49,52-54,56,59,109-111 are elevated in AD, these are not
consistently correlatedwith disease severity or onlyweakly corre-
lated,12,51,90,112 and in dupilumab studies, responses of patients
with AD are regardless of their baseline IgE levels.113 Thus, it
is likely that IgE is a bystander in AD pathogenesis, rather than
a treatment target.114,115 Although periostin is implicated in the
TABLE II. Biomarkers as disease classifiers, potentially improving diagnosis by differentiating AD and psoriasis
Biomarker Full name Functional effect Abnormalities
NOS2 Inducible nitric oxidase synthase Catalyzing the production of nitric oxide, a toxic defense molecule
against infections, and a regulator of functional activity, growth,
and death of immune cells including T cells, antigen-presenting
cells, mast cells, neutrophils, and natural killer cells
Upregulated in psoriasis,
downregulated in AD
CCL27/CTACK Chemokine (C-C motif) ligand
27/cutaneous T-cell–attracting
chemokine
Expressed by keratinocytes. Mediates the migration of
lymphocytes into the skin by binding to CCR10
Upregulated in AD,
downregulated in psoriasis
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biomarker by some reports, evidence for a correlation with dis-
ease severity is weak.18,116,117 Curiously, despite some reports
on the correlation of the ‘‘itch cytokine,’’ IL-31, with disease
severity,62,118 more evidence is accumulating on the lack of
such correlation.102,119-121Predictive biomarkers
Tissue biomarkers predicting disease onset include TARC and
IgE in the umbilical cords of newborns122,123 and natural moistur-
izing factor levels in neonates’ skin,124 which are known to
strongly correlate with transepidermal water loss,23 another pre-
dictor of AD development in newborns.125,126 Moisturizers can
prevent AD in high-risk infants,127 and were shown to alter skin
microbiome and reduce skin pH in this population.128 Other bio-
markers may predict AD persistence (eg, low serum vascular
endothelial growth factor [VEGF]).129
Because of the heterogeneous nature of AD pathophysiology,
AD therapies targeting individual pathways are unlikely to result
in high levels of response by all patients with AD,130,131 as seen in
psoriasis with IL-17/IL-23 targeting.132 Thus, using biomarkers
that can identify patient subsets that are more likely to respond
to individual drugs or pathway antagonism would be beneficial.
AD clinical trials have increasingly incorporated mechanistic an-
alyses to assess potential biomarkers in both skin and blood
(Table IV).96,133,134 Also, as AD symptoms fluctuate over time,
biomarkers have the potential to provide objective insights into
patient response to treatment and elucidate the mechanism of ac-
tion of a drug. Biomarkers can either be common to all treatments
(‘‘disease response biomarkers’’) or can be specific to individual
treatments (‘‘treatment-specific biomarkers’’). For example,
data from the phase 2 tralokinumab (IL-13 blocker) trial in AD
have identified dipeptidyl peptidase-4 as a potential treatment
response biomarker for IL-13 inhibition,4 and in asthma, periostin
was identified as a response biomarker to IL-13 inhibition.135,136
Another example is the mAb inhibiting IL-22, fezakinumab, to
which patients with AD with high IL-22 levels in skin biopsies
at baseline were significantly more likely to respond.133 Other
treatment-specific predictive biomarkers include CXCL9 (TH1/
interferon-related) for cyclosporine and CXCL2 (TH17-related)
for dupilumab.137 Although broad immune-suppressors (eg,
methotrexate or azathioprine) were also studied in AD, no de-
creases in individual cytokine levels significantly correlated
with response across agents.138
Recently, CCL22/MDC was found as the best biomarker of
disease response across studies using different therapeutics,137 as
baseline CCL22/MDC expression correlated with future clinical
improvement across multiple studies at various time points,including topical treatment (crisaborole), systemic immunosup-
pressant (cyclosporine), and targeted treatment (fezakinumab).137CCL17/TARC AS A BIOMARKER OF AD
Since CCL17/TARC was introduced to the field, primarily in
Japan, it was reported as the most reliable biomarker studied,15
sensitive to fluctuations in clinical findings.20,24,27,28,38,101-103
CCL17/TARC is a CC chemokine discovered in 1996 by Imai
et al,139 constitutively expressed in the thymus and a member of
the TH2 chemokine family that attracts CC chemokine receptor
4–positive cells. Of note, thymus size also correlates with AD ac-
tivity, and thymectomy may reduce the risk of AD.140,141 TH2-
type cells and related products are significantly upregulated
across various AD populations.43,59,65,142-144 In AD lesional
skin, CCL17/TARC is expressed on keratinocytes in the
epidermis, vascular endothelial cells, T cells, and dendritic
cells.20,142 In Japan, serum CCL17/TARC levels have been
measured commercially under health insurance support since
2008. Currently, after more than a decade of experience in pa-
tients with AD, CCL17/TARC has become a useful clinical
biomarker for monitoring the efficacy of treatment and for
ensuring successful treatment outcomes in the Japanese
population.101
The normal level of serum CCL17/TARC in healthy adults is
less than 450 pg/mL; its level in healthy children differs depend-
ing on age.31 Several investigations have also confirmed a high
correlation between the AD severity and serum CCL17/TARC
levels in pediatric patients.27,29,31,33,37, Moreover, increased
CCL17/TARC levels from umbilical cord blood may even predict
AD in infancy.122 Reports on the correlations between CCL17/
TARC levels in the skin and clinical severity are sparse.21,25,145
Monitoring of serum CCL17/TARC levels could also be
harnessed as an educational tool, improving patients’ adherence
to treatment regimens. Patients can view their own disease
activity as an objective number, and a rapid fall in the initially
high serum CCL17/TARC levels due to adequate treatment can
surely enhance compliance, a known pitfall in AD manage-
ment.146 Moreover, patients receiving proactive treatment
showed decreased but still high serum CCL17/TARC levels and
were thus motivated to receive continuous therapy. CCL17/
TARC is also reliable for assessing nonvisible/subclinical yet
active AD-related inflammation, and high levels of CCL17/
TARC may suggest frequent AD relapses even after clinical res-
olution, where a relatively thorough proactive treatment may be
recommended.35
Nevertheless, the limitations of CCL17/TARC as an AD
biomarker should also be acknowledged. Elevated serum
CCL17/TARC level is not specific to AD, and could also be
TABLE III. Potential biomarkers reported to strongly and significantly correlate with clinical severity indices of AD (correlation
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Esaki et al65§ (LS-B)
Ungar et al58 (LS/NL-B)
Wen et al43 (NL-B)k
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Suarez-Farinas et al42 (LS-B)
Szegedi et al67 (LS-ISF)
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S100A7/12 (>5) — — — — — Suarez-Farinas et al42 (LS-B)
Tintle et al41 (LS-B)k
Suarez-Farinas et al54 (LS-B)
Ungar et al58 (LS1/NL-B)
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Sanyal et al59 (LS-B)
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Gittler et al84 (NL-B)
Esaki et al65 (LS-B)
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Esaki et al65 (LS-B)
Guttman-Yassky et al68 (LS-TS)k













B, Skin biopsy; C, cell count; Corr, correlation; ECP, eosinophil cationic protein; E, ELISA; ECL, electrochemiluminescence immunoassay; EMD, Erenna immunoassay; F, flow
cytometry; FEIA, fluorescent enzyme immunoassays; IC, ImmunoCap system; IF, immunofluorescence; IRMA, immunoradiometric assay; ISF, interstitial fluid; K, Kendall rank
correlation; L, Luminex; LDH, lactate dehydrogenase; LRA, linear regression analysis; LS, lesional; N, nephelometric method; NA, not applicable/available; NL, nonlesional; O,
OLINK proteomics; PARC, pulmonary and activation-regulated chemokine; R, RNA-sequencing; RIA, ECP radioimmunoassay; SCORAD, SCORing of Atopic Dermatitis; TEWL,
transepidermal water loss; TS, tape-strips.
*Correlated with SCORAD components and not with the total SCORAD.
Pediatric cohort.
Correlated with Six Area, Six Sign AD/body surface area/Leicester severity score/scoring system as described by Costa et al.89
§Correlated with TEWL.
kP <_ .1.
{Performed on monocyte-derived circulating dendritic cells.
#Log2(IgE) was correlated with SCORAD.
**Correlated with pruritus.
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cutaneous T-cell lymphoma, drug eruption, pustular dermatosis,
and other skin diseases,147-149 as well as in hypereosinophilic syn-
drome, Hodgkin lymphoma, and other internal disorders.150,151
Also, some patients with severe AD and patients with nodular
prurigo or longstanding severe chronic lichenified lesions occa-
sionally show normal or even low serum CCL17/TARC levels.
Such cases may be explained by the heterogeneric pathomechan-
isms of AD. In addition, the added benefit of CCL17/TARC
beyond a surrogate of clinical severity, for example, as a predictor
of therapeutic response or as a reliable biomarker for clinical tri-
als, still needs to be validated in future studies, using repeated
testing.AD BIOMARKERS ACROSS DISEASE PHENOTYPES
Two T-cell subsets—TH2 and TH22—are commonly activated
across AD subtypes, yet specific biomarkers vary among different
populations. Some examples of AD subtypes where phenotypic
features may be explained by biomarker-related findings follow.Patients with AD in different ethnicities
The Asian AD phenotype is characterized by greater expres-
sion of TH17-related markers (IL-17A, IL-19, CCL20) along with
upregulation of IL-22 and the IL-17/IL-22–induced S100A12 in
comparison to European-American patients with AD, but not to
the levels found in psoriasis.43,144,152 This is particularly signifi-
cant given most Asian patients with AD have extrinsic AD
(high IgE levels), which tends to be associated with lower TH17
expression than intrinsic AD.144 These data suggest that Asian pa-
tients with AD present an immune dysregulation that is between
European-American AD and psoriasis, and correlates well with
the clinical phenotype of Asian AD, characterized by relatively
well demarcated, psoriasiform lesions.143 Black patients with
AD largely lack FLG mutations, in parallel with TH2/TH22predominance and TH1/TH17 attenuation.
59 Thesemay contribute
to the lower rate of transepidermal water loss in black AD and to
the atypical lichenified phenotype commonly seen in black pa-
tients with AD, potentially resulting from TH22
overexpression.143,153Age-related changes in AD
Elderly patients (>_61 years old) with AD present a relative
decrease in TH2/TH22 biomarkers with parallel increase in TH1/
TH17 biomarkers, and a less pronounced barrier defect.
86 The
latter finding may contribute to the clinical observation of allergic
sensitization as part of the atopic march, following AD initiation
only at young age, and supports the notion that impaired barrier
likely plays a major role in this process.
In addition, early-onset AD in infants is molecularly similar to
psoriasis with a relatively dominant TH17-related skewing,
65 in
line with the extensor distribution of lesions in this age group,
resembling that of psoriasis.Biomarkers in association with AD comorbidities
In pediatric patients with AD, KRT5, KRT14, KRT16, FLG
breakdown products, and AD clinical severity were predictive of
concomitant food allergy.154 FLG mutations with suppressed
levels of FLG expression predispose to AD, but are also associ-
ated with other diseases including asthma, irritant and allergic
contact dermatitis, and alopecia areata.155 High levels of IgE
and dysfunctional/low levels of FLG may predispose patients
with AD to food allergy as part of the atopic march.156Presence of Staphylococcus aureus colonization in
AD
Finally, patients with AD colonized with S aureus have higher
levels of type 2 biomarkers (including eosinophils, IgE, CCL17/
TABLE IV. Potential biomarkers reported to strongly and significantly correlate with clinical therapeutic response in AD
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Eotaxin-3/CCL26 (>_3) — — — — — Hamilton et al98 (LS-B)
Khattri et al91 (LS-B)















E S 2019 54 Khattri et al91 (LS-B)









B, Skin biopsy; Corr, correlation; E, ELISA; ECL, electrochemiluminescence immunoassay; LRA, linear regression analysis; LS, lesional; N, nephelometric method; NL,
nonlesional; PARC, pulmonary and activation-regulated chemokine; TS, tape-strips.
*Correlated with pruritus.
P <_ .1.
Correlated with Leicester severity score/Investigator’s Static Global Assessment.
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with more severe clinical parameters, including all severity
scores, barrier dysfunction (by transepidermal water loss), and
greater allergen sensitization.157MINIMALLY INVASIVE BIOMARKERS
Through studies of skin biopsies, biomarkers of the immune
milieu and barrier alterations of AD have been defined and
facilitated therapeutic development. The inflammatory profile of
AD is characterized by TH2 and TH22 skewing, with variable TH1
and TH17 components, depending on the disease subset (as
detailed above).43,59,143,144 The barrier defects of AD include ab-
normalities in epidermal differentiation (FLG, loricrin, etc), tight
junction (claudins), and lipid products (elongation of very long
chain fatty acids-like 3 [ELOVL3], fatty acid 2-hydroxylase
[FA2H], etc). Skin biopsies were also instrumental and sensitive
in providing useful information on early and late changes with
various treatments. Treatment response biomarkers provideimportant information of how well a certain drug is able to inhibit
its direct target as well as other immune axes, and what is the rela-
tionship between inhibition of certain immune pathways/products
and restoration of the barrier abnormalities characterizing AD, as
well as clinical measures of the disease. Blood represents an
easier accessible source of biomarkers, due to the relatively
easy collection by blood withdrawal, in contrast to the invasive
skin biopsy necessary for the assessment of biomarkers in the
skin. In addition, blood levels may more objectively represent
overall skin involvement, whereas skin biopsy represents only
the skin where the biopsy is performed. Unfortunately, although
skin biopsies accurately reflect disease severity and robust
changes can be found early in the skin of patients with AD with
various treatments, changes in blood may be more subtle and/or
may take longer to occur.20,158 In addition, some key AD bio-
markers in skin (ie, CCL26/exotoxin-3)84 are not well detected
in blood, limiting the use of blood as a surrogate to skin biopsies.
Biopsies collected from skin could be further divided into lesional
and nonlesional samples. Perhaps counterintuitively, mRNA
TABLE V. GRADE evidence profile: Accumulated data on potential biomarkers correlating with disease severity in AD*
Biomarker











Biomarkers correlating with severity in nontreated adult AD
CCL17/TARC
14; 1,136
0.58 No serious limitations
for blood; for skin—
limited number of












Very high (in blood)
IgE
11; 421
0.62 No serious limitations No serious
inconsistency among













0.62 No serious limitations
for blood; for skin—
limited evidence






















































0.54 Sparse data in blood by
our criteria. Limited
number of patients in





















0.46 No serious limitations
for skin. Only
proteomic data were





















0.59 Limited evidence in
blood, no evidence in
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TABLE V. (Continued)
Biomarker

























0.63 Very limited data in
adult skin; no data











0.59 No data were reported
in adult skin by our
criteria. The largest
study in adult blood








Biomarkers correlating with severity in nontreated pediatric AD
CCL17/TARC
9; 559
0.56 No serious limitations
in blood. No data
were reported in











0.66 No serious limitations
in blood. No data
were reported in






























0.45 Limited evidence in
pediatric blood; no
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NA Very limited number of
studies and subjects
in pediatric skin; no
evidence in pediatric










0.5 Very limited number of
studies and subjects
in both skin and
blood by our criteria
In blood, correlation
was found with body










0.43 Limited evidence in
pediatric skin; no
evidence in pediatric
blood by our criteria.
Tape-stripped
pediatric skin only
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TABLE V. (Continued)
Biomarker











Biomarkers showing decreased levels in correlation with clinical improvement in longitudinal, topical treatment studies
CCL17/TARC,
CCL22/MDC,
1; 20 (for both)
NA Limited data and only
with an emollient.
Correlation was

























Biomarkers showing decreased levels in correlation with clinical improvement in longitudinal, systemic treatment studies
CCL17/TARC
6; 170













































0.56 Limited evidence in











0.56 Limited evidence in
skin; sparse evidence




















EASI, Eczema Area and Severity Index; ECP, eosinophil cationic protein; LDH, lactate dehydrogenase; NA, not applicable because only 1 report was included by our criteria;
PARC, pulmonary and activation-regulated chemokine; SCORAD, SCORing of Atopic Dermatitis.
*Based on Tables III and IV, only studies with a significant positive correlation with a correlation coefficient of >_0.4 were included.
Baseline CCL22/MDC expression in skin correlated with future clinical improvement in a report analyzing data across multiple studies (using both topical and systemic therapies)
at various time points.108
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treated patients with AD show higher and more significant corre-
lations with SCORing of Atopic Dermatitis, including general
inflammatory (metalloproteinase 12 [MMP12])- and proliferation
(keratin 16 [KRT16])-related markers, as well as markers related
to TH22 (IL-22), TH17 (CXCL1), and TH17/TH22 (S100A9).
58
Moreover, nonlesional untreated skin data better correlate with
serum data as compared with lesional skin, whereas correlations
between lesional skin and serum are sparse.43,58 A possible expla-
nation is that lesional AD skin bears a highly inflamedbackground, making the AD-specific biomarkers harder to iden-
tify and dissect due to a dilution phenomenon of innate cytokines.
Furthermore, because nonlesional AD skin is not normal and yet
not as inflamed as lesional skin, it provides a unique window for
assessing AD dissemination to apparently uninvolved skin, and
interventions that normalize nonlesional skin have the hypothetic
potential to also prevent AD development.
Nevertheless, although skin biopsies are feasible in proof-of-
concept studies in which it is crucial to understand the mechanism
of action, and are highly informative, biopsies may be associated
TABLE VI. Comparison of biomarker assessment by tape-strips and full-thickness skin biopsies
Parameter Tape-strips Skin biopsies
Detection rates Limited sample detection rates of 50% or even less in some
studies23,154,159,160
Typically, very high
Depth of tissue sampled Stratum corneum and some of the stratum granulosum Entire epidermis and dermis (when punch biopsies are used)
Detection of key TH2/TH22,
AD-related biomarkers





Captured well (eg, terminal differentiation markers such as
FLG and LOR, lipid-related biomarkers such as ELOVL1-
7).9,23,68,154,159,163 Expression of some biomarkers was
correlated with biopsies in the same individuals.164
A recent report suggested tape-stripped skin may even
capture barrier-related changes better than biopsied skin in
early disease81
Usually captured well. Barrier-related changes can be located
at specific areas of the skin
Advantages Minimally invasive, nonscarring, allows repeated testing even
in pediatric patients
Provides enough tissue for various laboratory studies,
including for full-thickness immunohistochemistry studies
revealing structural changes
Disadvantages Tissue processing is time-consuming and technically
challenging; potential differences in depth of tape-stripped
skin, location of biomarkers, and structural changes (eg,
epidermal thickness) within the skin cannot be captured.
Hyperlasia-related biomarkers (eg, K16 and Ki67) are not
well captured
Painful, scarring (including hypertrophic/keloids), might be
complicated by infections, poor healing
ELOVL, Elongation of very long chain fatty acids protein; LOR, loricrin.
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to use them in the setting of large-scale clinical trials and
longitudinal studies, as well as in pediatric studies. Furthermore,
incorporating skin and blood biomarker testing into large clinical
trials, longitudinal studies, and in the clinic may be challenging
and, if it is to be adopted in the future, will require very simple
testing methods.
Consequently, there is a large unmet need for development of
minimally invasive cutaneous biomarkers that capture the AD
profile of lesional and nonlesional skin. Recently, tape-strips
studies, collecting stratum corneum proteins from both adults
and children with AD, showed promise in defining key
disease features.68,106,159-161 These include studies of predefined
sets of proteins and genes, as well as a limited-scope
RNAseq.68,106,159,160,162 Similar to mRNA data from skin bi-
opsies, tape-strips from both lesional and nonlesional skin show
significant correlations with disease severity.68,93,159,160 Compar-
isons of variable aspects of tape-strips and biopsies are presented
in Table VI, including disadvantages that may limit the use of
tape-strips in settings of clinical trials or longitudinal studies.
Recently, transcriptomic studies by tape-strip collection in young
children and adults with AD showed improved detection rates of
close to 100% per sample and per marker, perhaps enabling this
approach in larger-scale studies, without losing data.9,68 This
may indicate that in the future it may be feasible to use tape-
strips in larger clinical trials and longitudinal studies, and even
in the clinic.Conclusions
The accessibility of the skin makes it the perfect tissue for
investigation of disease mechanisms, and bench-to-bedside trans-
lational approaches are rapidly facilitating the development of
novel therapeutics for inflammatory skin diseases. Tissue-derived
biomarkers may further accelerate clinical trials and allow better
reproducibility and rigor.165 Nevertheless, the discovery of anovel, validated disease-related biomarker is demanding and re-
quires multiple steps, from the first detection of the potential
tissue-derived factor to the final confirmation and acceptance by
regulatory organizations.
AD, a common yet complex skin disease, stemming from
immune dysregulations as well as epidermal barrier abnormal-
ities, still poses a therapeutic challenge. The ‘‘one-size-fits-all’’
approach does not always apply for AD, because diverse disease
phenotypes have been recognized, and therapeutic response may
vary on the basis of their clinical and molecular differences.
Indeed, a survey of AD specialists (IEC councilors and associ-
ates) strongly supports the combination of clinical evaluationwith
biomarkers’ assessments for stratification of patients with AD due
to the large heterogeneity of the disease. Despite the relatively
easy inspection of the skin by physical examination, clinical
observations may not fully appreciate skin abnormalities, and are
not entirely objective. This is emphasized by the relatively normal
clinical appearance of AD nonlesional skin, while tissue assess-
ments unearth significant immune and barrier dysregulations,
resembling lesional skin.42,166 As we move toward more targeted
therapies, AD biomarkers are important to appreciate patient-
specific molecular dysregulations that differ between various
AD subtypes. Because biologics are expensive, characterization
of biomarkers that predict which patients will likely benefit
most from these targeted biologics is essential. Ideally, a validated
set of reliable biomarkers using minimally invasive methods will
allow the implementation of precision medicine in AD, improve
patient management, and expedite the development of novel
therapeutics.
Because a biomarker should be assessed repeatedly, especially
in the context of treatment monitoring or longitudinal studies, the
preference of less-invasive methods over skin biopsies is well
understood. Furthermore, skin biopsies are even harder to obtain
in the pediatric population, in which the burden of AD is most
significant. It is thus not surprising that alternative methods for
skin sampling are emerging, with tape-strips, a minimally
FIG 1. Potential biomarkers for AD in nonlesional and lesional AD skin (using both biopsies and tape-strips,
top) as well as circulating potential biomarkers in blood of patients with AD (bottom). LDH, Lactate
dehydrogenase.
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showing promise in both adult and pediatric AD.9,68,81,154,159,160
A biomarker should be biologically relevant and linked to
disease mechanism.165 AD is characterized by robust systemic
and cutaneous immune activation,167 with a dominant TH2-
skewing that is shared across AD subtypes.168 Currently, some
clinicians are already assessing few potential AD-related blood
biomarkers to complement the physical examination and assess
severity more accurately. These include nonspecific markers of
inflammation and atopy. Nevertheless, the chemokine with the
greatest evidence-based support to become a potential AD
biomarker, at both baseline and following therapy, is CCL17/
TARC, a chemoattractant of TH2 cells. Although CCL17/TARC
is implicated in other atopic diseases as well, including asthma
and allergic rhinitis,169,170 correlation with clinical severity was
established only in patients with AD.27 Moreover, we were able
to find more than 20 publications supporting the robust correla-
tion of serum CCL17/TARC with AD clinical severity, mainly
SCORing of Atopic Dermatitis, in both children and adults.
Additional emerging potential biomarkers include other
TH2-related chemokines, such as CCL18/pulmonary and
activation-regulated chemokine, CCL22/MDC (recently reported
to consistently predict therapeutic response across different treat-
ments),137 CCL26/eotaxin-3, CCL27/CTACK, and the key TH2
and TH22 cytokines, that is, IL-13 and IL-22, respectively. In
comparison to TH2-related chemokines, cytokines were less
commonly reported as blood biomarkers for AD and were mostly
found to correlate with severity when assessed in skin.
In conclusion, the potential of biomarkers in AD is yet to be
fully elucidated. The significant burden of the disease, itsheterogeneity with increasingly recognized various subtypes,
and the challenges of developing a ‘‘magic bullet’’ that benefits all
patients despite the progression of multiple novel therapies
advocate for a precision medicine approach. This approach would
benefit from a set of disease-specific biomarkers that will further
facilitate AD research and improve patient management; howev-
er, as demonstrated by our GRADE-based evaluation, evidence
on biomarkers is still lacking.
New studies using more minimal techniques such as tape-
strips, including pretreatment and posttreatment assessments, in
which biomarker dynamics are closely monitored in relation to
therapeutic response, are needed to improve the validity and
relevance of biomarkers in AD. Large-scale clinical trials with
extensive biomarker evaluation, including patients with variable
AD phenotypes (eg, variable races and ages), are critical to
establish the potential role of biomarkers in AD management.
These may lead in the future to a clinical approach using
biomarkers as a practical clinical tool where AD treatment will
be personally tailored.
The figure was created with BioRender.com.REFERENCES
1. Bieber T, Traidl-Hoffmann C, Schappi G, Lauener R, Akdis C, Schmid-Grendl-
meier P. Unraveling the complexity of atopic dermatitis: the CK-CARE approach
towards precision medicine. Allergy 2020;75:2936-8.
2. Renert-Yuval Y, Guttman-Yassky E. What’s new in atopic dermatitis. Dermatol
Clin 2019;37:205-13.
3. Han Y, Chen Y, Liu X, Zhang J, Su H, Wen H, et al. Efficacy and safety of du-
pilumab for the treatment of adult atopic dermatitis: a meta-analysis of random-
ized clinical trials. J Allergy Clin Immunol 2017;140:888-91.e6.
J ALLERGY CLIN IMMUNOL
nnn 2021
14 RENERT-YUVAL ET AL4. Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K,
et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
J Allergy Clin Immunol 2019;143:135-41.
5. Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taieb A, et al. Efficacy
and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with
moderate-to-severe atopic dermatitis inadequately controlled by topical cortico-
steroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am
Acad Dermatol 2018;78:863-71.e11.
6. Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R,
et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a
phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose
study. J Am Acad Dermatol 2019;80:913-21.e9.
7. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guide-
lines, 1: introduction—GRADE evidence profiles and summary of findings tables.
J Clin Epidemiol 2011;64:383-94.
8. Garzorz-Stark N, Krause L, Lauffer F, Atenhan A, Thomas J, Stark SP, et al. A
novel molecular disease classifier for psoriasis and eczema. Exp Dermatol
2016;25:767-74.
9. He H, Bissonnette R, Wu J, Diaz A, Saint-Cyr Proulx E, Maari C, et al. Tape
strips detect distinct immune and barrier profiles in atopic dermatitis and psoria-
sis. J Allergy Clin Immunol 2021;147:199-212.
10. Quaranta M, Knapp B, Garzorz N, Mattii M, Pullabhatla V, Pennino D, et al. In-
traindividual genome expression analysis reveals a specific molecular signature of
psoriasis and eczema. Sci Transl Med 2014;6:244ra90.
11. Vekaria AS, Brunner PM, Aleisa AI, Bonomo L, Lebwohl MG, Israel A, et al.
Moderate-to-severe atopic dermatitis patients show increases in serum C-reac-
tive protein levels, correlating with skin disease activity. F1000Res 2017;6:
1712.
12. Morishima Y, Kawashima H, Takekuma K, Hoshika A. Changes in serum lactate
dehydrogenase activity in children with atopic dermatitis. Pediatr Int 2010;52:
171-4.
13. Kou K, Aihara M, Matsunaga T, Chen H, Taguri M, Morita S, et al. Association
of serum interleukin-18 and other biomarkers with disease severity in adults with
atopic dermatitis. Arch Dermatol Res 2012;304:305-12.
14. Mizawa M, Yamaguchi M, Ueda C, Makino T, Shimizu T. Stress evaluation in
adult patients with atopic dermatitis using salivary cortisol. Biomed Res Int
2013;2013:138027.
15. Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-
Koomen C, et al. Biomarkers for atopic dermatitis: a systematic review and
meta-analysis. Curr Opin Allergy Clin Immunol 2015;15:453-60.
16. Kagi MK, Joller-Jemelka H, Wuthrich B. Correlation of eosinophils, eosinophil
cationic protein and soluble interleukin-2 receptor with the clinical activity of
atopic dermatitis. Dermatology 1992;185:88-92.
17. Ariens LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwen-
hoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat
adult atopic dermatitis patients: first clinical and biomarker results from the Bio-
Day registry. Allergy 2020;75:116-26.
18. Kou K, Okawa T, Yamaguchi Y, Ono J, Inoue Y, Kohno M, et al. Periostin levels
correlate with disease severity and chronicity in patients with atopic dermatitis.
Br J Dermatol 2014;171:283-91.
19. Czech W, Krutmann J, Schopf E, Kapp A. Serum eosinophil cationic protein
(ECP) is a sensitive measure for disease activity in atopic dermatitis. Br J Derma-
tol 1992;126:351-5.
20. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al.
Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus
and activation-regulated chemokine level is closely related with disease activity.
J Allergy Clin Immunol 2001;107:535-41.
21. Morita E, Takahashi H, Niihara H, Dekio I, Sumikawa Y, Murakami Y, et al. Stra-
tum corneum TARC level is a new indicator of lesional skin inflammation in
atopic dermatitis. Allergy 2010;65:1166-72.
22. Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, Bito T, et al. IFN-
gamma-inducible expression of thymus and activation-regulated chemokine/
CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes
and their roles in atopic dermatitis. Int Immunol 2002;14:767-73.
23. McAleer MA, Jakasa I, Hurault G, Sarvari P, McLean WHI, Tanaka RJ, et al. Sys-
temic and stratum corneum biomarkers of severity in infant atopic dermatitis
include markers of innate and T helper cell-related immunity and angiogenesis.
Br J Dermatol 2019;180:586-96.
24. Fujisawa T, Fujisawa R, Kato Y, Nakayama T, Morita A, Katsumata H, et al. Pres-
ence of high contents of thymus and activation-regulated chemokine in platelets
and elevated plasma levels of thymus and activation-regulated chemokine and
macrophage-derived chemokine in patients with atopic dermatitis. J Allergy
Clin Immunol 2002;110:139-46.25. He H, Del Duca E, Diaz A, Kim HJ, Gay-Mimbrera J, Zhang N, et al. Mild atopic
dermatitis lacks systemic inflammation and shows reduced nonlesional skin ab-
normalities [published online ahead of print October 1, 2020]. J Allergy Clin Im-
munol. https://doi.org/10.1016/j.jaci.2020.08.041.
26. Leung TF, Ma KC, Hon KL, Lam CW, Wan H, Li CY, et al. Serum concentration
of macrophage-derived chemokine may be a useful inflammatory marker for as-
sessing severity of atopic dermatitis in infants and young children. Pediatr Allergy
Immunol 2003;14:296-301.
27. Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koo-
men C, et al. Serum thymus and activation-regulated chemokine (TARC) and
cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases:
TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy
Clin Immunol 2004;113:334-40.
28. Jahnz-Rozyk K, Targowski T, Paluchowska E, OwczarekW, Kucharczyk A. Serum
thymus and activation-regulated chemokine, macrophage-derived chemokine
and eotaxin as markers of severity of atopic dermatitis. Allergy 2005;60:685-8.
29. Song TW, Sohn MH, Kim ES, Kim KW, Kim KE. Increased serum thymus and
activation-regulated chemokine and cutaneous T cell-attracting chemokine levels
in children with atopic dermatitis. Clin Exp Allergy 2006;36:346-51.
30. Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N. Serum
levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important
markers of severity in infantile atopic dermatitis. Pediatr Allergy Immunol
2008;19:605-13.
31. Fujisawa T, Nagao M, Hiraguchi Y, Katsumata H, Nishimori H, Iguchi K, et al.
Serum measurement of thymus and activation-regulated chemokine/CCL17 in
children with atopic dermatitis: elevated normal levels in infancy and age-
specific analysis in atopic dermatitis. Pediatr Allergy Immunol 2009;20:633-41.
32. van Velsen SG, Knol MJ, Haeck IM, Bruijnzeel-Koomen CA, Pasmans SG. The
Self-administered Eczema Area and Severity Index in children with moderate to
severe atopic dermatitis: better estimation of AD body surface area than severity.
Pediatr Dermatol 2010;27:470-5.
33. Machura E, Rusek-Zychma M, Jachimowicz M, Wrzask M, Mazur B, Kasperska-
Zajac A. Serum TARC and CTACK concentrations in children with atopic derma-
titis, allergic asthma, and urticaria. Pediatr Allergy Immunol 2012;23:278-84.
34. Furue M, Matsumoto T, Yamamoto T, Takeuchi S, Esaki H, Chiba T, et al. Cor-
relation between serum thymus and activation-regulated chemokine levels and
stratum corneum barrier function in healthy individuals and patients with mild
atopic dermatitis. J Dermatol Sci 2012;66:60-3.
35. Kataoka Y. Thymus and activation-regulated chemokine as a clinical biomarker in
atopic dermatitis. J Dermatol 2014;41:221-9.
36. Landheer J, de Bruin-Weller M, Boonacker C, Hijnen D, Bruijnzeel-Koomen C,
Rockmann H. Utility of serum thymus and activation-regulated chemokine as a
biomarker for monitoring of atopic dermatitis severity. J Am Acad Dermatol
2014;71:1160-6.
37. Ahrens B, Schulz G, Bellach J, Niggemann B, Beyer K. Chemokine levels in
serum of children with atopic dermatitis with regard to severity and sensitization
status. Pediatr Allergy Immunol 2015;26:634-40.
38. Gu CY, Gu L, Dou X. Serum levels of thymus and activation-regulated chemo-
kine can be used in the clinical evaluation of atopic dermatitis. Int J Dermatol
2015;54:e261-5.
39. Hulshof L, Overbeek SA, Wyllie AL, Chu M, Bogaert D, de Jager W, et al.
Exploring immune development in infants with moderate to severe atopic derma-
titis. Front Immunol 2018;9:630.
40. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al.
Serum macrophage-derived chemokine (MDC) levels are closely related with
the disease activity of atopic dermatitis. Clin Exp Immunol 2002;127:270-3.
41. Tintle S, Shemer A, Suarez-Farinas M, Fujita H, Gilleaudeau P, Sullivan-Whalen
M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and
biomarkers for therapeutic response. J Allergy Clin Immunol 2011;128:
583-93.e1-4.
42. Suarez-Farinas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, Cardinale I,
et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differ-
entiation defects and variable immune abnormalities. J Allergy Clin Immunol
2011;127:954-64.e1-4.
43. Wen HC, Czarnowicki T, Noda S, Malik K, Pavel AB, Nakajima S, et al. Serum
from Asian patients with atopic dermatitis is characterized by TH2/TH22 activa-
tion, which is highly correlated with nonlesional skin measures. J Allergy Clin
Immunol 2018;142:324-8.e11.
44. Gunther C, Bello-Fernandez C, Kopp T, Kund J, Carballido-Perrig N, Hinteregger
S, et al. CCL18 is expressed in atopic dermatitis and mediates skin homing of hu-
man memory T cells. J Immunol 2005;174:1723-8.
45. Angelova-Fischer I, Hipler UC, Bauer A, Fluhr JW, Tsankov N, Fischer TW, et al.
Significance of interleukin-16, macrophage-derived chemokine, eosinophil
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
RENERT-YUVAL ET AL 15cationic protein and soluble E-selectin in reflecting disease activity of atopic
dermatitis–from laboratory parameters to clinical scores. Br J Dermatol 2006;
154:1112-7.
46. Hashimoto S, Nakamura K, Oyama N, Kaneko F, Tsunemi Y, Saeki H, et al.
Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived
dendritic cells reflects the disease activity in patients with atopic dermatitis.
J Dermatol Sci 2006;44:93-9.
47. Brunner PM, He H, Pavel AB, Czarnowicki T, Lefferdink R, Erickson T, et al.
The blood proteomic signature of early-onset pediatric atopic dermatitis shows
systemic inflammation and is distinct from adult long-standing disease. J Am
Acad Dermatol 2019;81:510-9.
48. Tsuboi H, Kouda K, Takeuchi H, Takigawa M, Masamoto Y, Takeuchi M, et al. 8-
hydroxydeoxyguanosine in urine as an index of oxidative damage to DNA in the
evaluation of atopic dermatitis. Br J Dermatol 1998;138:1033-5.
49. Yoshizawa Y, Nomaguchi H, Izaki S, Kitamura K. Serum cytokine levels in atopic
dermatitis. Clin Exp Dermatol 2002;27:225-9.
50. Kaminishi K, Soma Y, Kawa Y, Mizoguchi M. Flow cytometric analysis of IL-4,
IL-13 and IFN-gamma expression in peripheral blood mononuclear cells and
detection of circulating IL-13 in patients with atopic dermatitis provide evidence
for the involvement of type 2 cytokines in the disease. J Dermatol Sci 2002;29:
19-25.
51. Aral M, Arican O, Gul M, Sasmaz S, Kocturk SA, Kastal U, et al. The relation-
ship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease
severity in children with atopic dermatitis. Mediators Inflamm 2006;2006:73098.
52. Salomon J, Baran E. The role of selected neuropeptides in pathogenesis of atopic
dermatitis. J Eur Acad Dermatol Venereol 2008;22:223-8.
53. Wu KG, Li TH, Chen CJ, Cheng HI, Wang TY. Correlations of serum interleukin-
16, total IgE, eosinophil cationic protein and total eosinophil counts with disease
activity in children with atopic dermatitis. Int J Immunopathol Pharmacol 2011;
24:15-23.
54. Suarez-Farinas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman
Strong C, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17
immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Im-
munol 2013;132:361-70.
55. Zedan K, Rasheed Z, Farouk Y, Alzolibani AA, Bin Saif G, Ismail HA, et al.
Immunoglobulin E, interleukin-18 and interleukin-12 in patients with atopic
dermatitis: correlation with disease activity. J Clin Diagn Res 2015;9:WC01-5.
56. Glatz M, Buchner M, von Bartenwerffer W, Schmid-Grendelmeier P, Worm M,
Hedderich J, et al. Malassezia spp.-specific immunoglobulin E level is a marker
for severity of atopic dermatitis in adults. Acta Derm Venereol 2015;95:191-6.
57. Rosinska-Wieckowicz A, Czarnecka-Operacz M, Adamski Z. Selected immuno-
logical parameters in clinical evaluation of patients with atopic dermatitis. Post-
epy Dermatol Alergol 2016;33:211-8.
58. Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer A, et al. An
integrated model of atopic dermatitis biomarkers highlights the systemic nature of
the disease. J Invest Dermatol 2017;137:603-13.
59. Sanyal RD, Pavel AB, Glickman J, Chan TC, Zheng X, Zhang N, et al. Atopic
dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17
attenuation. Ann Allergy Asthma Immunol 2019;122:99-110.e6.
60. Mukai H, Noguchi T, Kamimura K, Nishioka K, Nishiyama S. Significance of
elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis.
J Dermatol 1990;17:477-81.
61. Halmerbauer G, Frischer T, Koller DY. Monitoring of disease activity by mea-
surement of inflammatory markers in atopic dermatitis in childhood. Allergy
1997;52:765-9.
62. Raap U, Weissmantel S, Gehring M, Eisenberg AM, Kapp A, Folster-Holst R. IL-
31 significantly correlates with disease activity and Th2 cytokine levels in chil-
dren with atopic dermatitis. Pediatr Allergy Immunol 2012;23:285-8.
63. Chen YL, Gutowska-Owsiak D, Hardman CS, Westmoreland M, MacKenzie T,
Cifuentes L, et al. Proof-of-concept clinical trial of etokimab shows a key role
for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med 2019;11:eaax2945.
64. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T,
et al. IL-22-producing ‘‘T22’’ T cells account for upregulated IL-22 in atopic
dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immu-
nol 2009;123:1244-52.e2.
65. Esaki H, Brunner PM, Renert-Yuval Y, Czarnowicki T, Huynh T, Tran G, et al.
Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin.
J Allergy Clin Immunol 2016;138:1639-51.
66. Koning H, Neijens HJ, Baert MR, Oranje AP, Savelkoul HF. T cell subsets and
cytokines in allergic and non-allergic children, I: analysis of IL-4, IFN-gamma
and IL-13 mRNA expression and protein production. Cytokine 1997;9:416-26.
67. Szegedi K, Lutter R, Res PC, Bos JD, Luiten RM, Kezic S, et al. Cytokine profiles
in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Ve-
nereol 2015;29:2136-44.68. Guttman-Yassky E, Diaz A, Pavel AB, Fernandes M, Lefferdink R, Erickson T,
et al. Use of tape strips to detect immune and barrier abnormalities in the skin
of children with early-onset atopic dermatitis. JAMA Dermatol 2019;155:
1358-70.
69. Hon KL, Leung TF, Ma KC, Wong CK, Wan H, Lam CW. Serum concentration of
IL-18 correlates with disease extent in young children with atopic dermatitis. Pe-
diatr Dermatol 2004;21:619-22.
70. Inoue Y, Aihara M, Kirino M, Harada I, Komori-Yamaguchi J, Yamaguchi Y,
et al. Interleukin-18 is elevated in the horny layer in patients with atopic derma-
titis and is associated with Staphylococcus aureus colonization. Br J Dermatol
2011;164:560-7.
71. Park DS, Youn YH. Clinical significance of serum interleukin-18 concentration in
the patients with atopic dermatitis [in Korean]. Korean J Lab Med 2007;27:
128-32.
72. Pavel AB, Zhou L, Diaz A, Ungar B, Dan J, He H, et al. The proteomic skin pro-
file of moderate-to-severe atopic dermatitis patients shows an inflammatory signa-
ture. J Am Acad Dermatol 2020;82:690-9.
73. Suwarsa O, Adi S, Idjradinata P, Sutedja E, Avriyanti E, Asfara A, et al. Inter-
leukin-18 correlates with interleukin-4 but not interferon-gamma production in
lymphocyte cultures from atopic dermatitis patients after staphylococcal entero-
toxin B stimulation. Asian Pac J Allergy Immunol 2017;35:54-9.
74. Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Asano N, Mitsui H, et al. Increased
serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with
atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol 2003;111:
592-7.
75. Hon KL, Leung TF, Ma KC, Li AM, Wong Y, Fok TF. Serum levels of cutaneous
T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of
atopic dermatitis in children. Clin Exp Dermatol 2004;29:293-6.
76. Morita H, Kitano Y, Kawasaki N. Elevation of serum-soluble E-selectin in atopic
dermatitis. J Dermatol Sci 1995;10:145-50.
77. Yamashita N, Kaneko S, Kouro O, Furue M, Yamamoto S, Sakane T. Soluble
E-selectin as a marker of disease activity in atopic dermatitis. J Allergy Clin
Immunol 1997;99:410-6.
78. Wolkerstorfer A, Savelkoul HF, de Waard van der Spek FB, Neijens HJ, van
Meurs T, Oranje AP. Soluble E-selectin and soluble ICAM-1 levels as markers
of the activity of atopic dermatitis in children. Pediatr Allergy Immunol 2003;
14:302-6.
79. Brunner PM, Suarez-Farinas M, He H, Malik K, Wen HC, Gonzalez J, et al. The
atopic dermatitis blood signature is characterized by increases in inflammatory
and cardiovascular risk proteins. Sci Rep 2017;7:8707.
80. He H, Li R, Choi S, Zhou L, Pavel A, Estrada YD, et al. Increased cardiovascular
and atherosclerosis markers in blood of older patients with atopic dermatitis. Ann
Allergy Asthma Immunol 2020;124:70-8.
81. Pavel AB, Renert-Yuval Y, Wu J, Del Duca E, Diaz A, Lefferdink R, et al. Tape-
strips from early-onset pediatric atopic dermatitis highlight disease abnormalities
in non-lesional skin. Allergy 2021;76:314-25.
82. Olesen CM, Holm JG, Norreslet LB, Serup JV, Thomsen SF, Agner T. Treatment
of atopic dermatitis with dupilumab: experience from a tertiary referral centre.
J Eur Acad Dermatol Venereol 2019;33:1562-8.
83. Hon KL, Ching GK, Ng PC, Leung TF. Exploring CCL18, eczema severity and
atopy. Pediatr Allergy Immunol 2011;22:704-7.
84. Gittler JK, Shemer A, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz KJ, Wang
CQ, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective
epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy
Clin Immunol 2012;130:1344-54.
85. Kagami S, Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Nakamura K, et al. Sig-
nificant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/
CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect
the disease activity of atopic dermatitis. Clin Exp Immunol 2003;134:309-13.
86. Zhou L, Leonard A, Pavel AB, Malik K, Raja A, Glickman J, et al. Age-specific
changes in the molecular phenotype of patients with moderate-to-severe atopic
dermatitis. J Allergy Clin Immunol 2019;144:144-56.
87. Oka T, Sugaya M, Takahashi N, Nakajima R, Otobe S, Kabasawa M, et al.
Increased interleukin-19 expression in cutaneous T-cell lymphoma and atopic
dermatitis. Acta Derm Venereol 2017;97:1172-7.
88. Konrad RJ, Higgs RE, Rodgers GH, Ming W, Qian YW, Bivi N, et al. Assessment
and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis us-
ing a sensitive and specific novel immunoassay. Sci Rep 2019;9:5211.
89. Costa C, Rilliet A, Nicolet M, Saurat JH. Scoring atopic dermatitis: the simpler
the better? Acta Derm Venereol 1989;69:41-5.
90. Furukawa H, Takahashi M, Nakamura K, Kaneko F. Effect of an antiallergic
drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 produc-
tion by PBMCs from patients with atopic dermatitis. J Dermatol Sci 2004;36:
165-72.
J ALLERGY CLIN IMMUNOL
nnn 2021
16 RENERT-YUVAL ET AL91. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al.
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory
pathways and reverses epidermal pathology. J Allergy Clin Immunol 2014;133:
1626-34.
92. Kwon YS, Oh SH, Wu WH, Bae BG, Lee HJ, Lee MG, et al. CC chemokines as
potential immunologic markers correlated with clinical improvement of atopic
dermatitis patients by immunotherapy. Exp Dermatol 2010;19:246-51.
93. Koppes SA, Brans R, Ljubojevic Hadzavdic S, Frings-Dresen MH, Rustemeyer T,
Kezic S. Stratum corneum tape stripping: monitoring of inflammatory mediators
in atopic dermatitis patients using topical therapy. Int Arch Allergy Immunol
2016;170:187-93.
94. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupi-
lumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J
Med 2014;371:130-9.
95. Pavel AB, Song T, Kim HJ, Del Duca E, Krueger JG, Dubin C, et al. Oral Janus
kinase/SYK inhibition (ASN002) suppresses inflammation and improves
epidermal barrier markers in patients with atopic dermatitis. J Allergy Clin Immu-
nol 2019;144:1011-24.
96. Guttman-Yassky E, Bissonnette R, Ungar B, Suarez-Farinas M, Ardeleanu M,
Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnor-
malities in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143:
155-72.
97. Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, et al. Crisaborole
and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy
Clin Immunol 2019;144:1274-89.
98. Hamilton JD, Suarez-Farinas M, Dhingra N, Cardinale I, Li X, Kostic A, et al.
Dupilumab improves the molecular signature in skin of patients with moderate-
to-severe atopic dermatitis. J Allergy Clin Immunol 2014;134:1293-300.
99. He H, Olesen CM, Pavel AB, Clausen ML, Wu J, Estrada Y, et al. Tape-strip pro-
teomic profiling of atopic dermatitis on dupilumab identifies minimally invasive
biomarkers. Front Immunol 2020;11:1768.
100. Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced
dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis
after short-term topical tacrolimus treatment. J Allergy Clin Immunol 2004;114:
887-95.
101. Yasukochi Y, Nakahara T, Abe T, Kido-Nakahara M, Kohda F, Takeuchi S, et al.
Reduction of serum TARC levels in atopic dermatitis by topical anti-
inflammatory treatments. Asian Pac J Allergy Immunol 2014;32:240-5.
102. Kyoya M, Kawakami T, Soma Y. Serum thymus and activation-regulated chemo-
kine (TARC) and interleukin-31 levels as biomarkers for monitoring in adult
atopic dermatitis. J Dermatol Sci 2014;75:204-7.
103. Gohar MK, Atta AH, Nasr MM, Hussein DN. Serum thymus and activation regu-
lated chemokine (TARC), IL-18 and IL-18 gene polymorphism as associative fac-
tors with atopic dermatitis. Egypt J Immunol 2017;24:9-22.
104. Bogaczewicz J,Malinowska K, Sysa-Jedrzejowska A,Wozniacka A.Medium-dose
ultravioletA1 phototherapy andmRNAexpression of TSLP, TARC, IL-5, and IL-13
in acute skin lesions in atopic dermatitis. Int J Dermatol 2016;55:856-63.
105. Kagami S, Saeki H, Komine M, Kakinuma T, Tsunemi Y, Nakamura K, et al.
Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratino-
cyte cell line, HaCaT cells. Clin Exp Immunol 2005;141:459-66.
106. Kezic S, O’Regan GM, Lutter R, Jakasa I, Koster ES, Saunders S, et al. Filaggrin
loss-of-function mutations are associated with enhanced expression of IL-1 cyto-
kines in the stratum corneum of patients with atopic dermatitis and in a murine
model of filaggrin deficiency. J Allergy Clin Immunol 2012;129:1031-9.e1.
107. Thijs JL, Drylewicz J, Fiechter R, Strickland I, Sleeman MA, Herath A, et al.
EASI p-EASI: utilizing a combination of serum biomarkers offers an objective
measurement tool for disease severity in atopic dermatitis patients. J Allergy
Clin Immunol 2017;140:1703-5.
108. Glickman JW, Dubin C, Renert-Yuval Y, Dahabreh D, Kimmel GW, Auyeung K,
et al. Cross-sectional study of blood biomarkers of patients with moderate to se-
vere alopecia areata reveals systemic immune and cardiovascular biomarker dys-
regulation. J Am Acad Dermatol 2021;84:370-80.
109. Laske N, Niggemann B. Does the severity of atopic dermatitis correlate with
serum IgE levels? Pediatr Allergy Immunol 2004;15:86-8.
110. Shaheen MA, Attia EA, Louka ML, Bareedy N. Study of the role of serum folic
acid in atopic dermatitis: a correlation with serum IgE and disease severity. Indian
J Dermatol 2011;56:673-7.
111. Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral
mycophenolate mofetil. Br J Dermatol 2000;143:385-91.
112. Thijs JL, Knipping K, Bruijnzeel-Koomen CA, Garssen J, de Bruin-Weller MS,
Hijnen DJ. Immunoglobulin free light chains in adult atopic dermatitis patients
do not correlate with disease severity. Clin Transl Allergy 2016;6:44.
113. Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in
atopic dermatitis. Immunotherapy 2015;7:1043-58.114. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic
dermatitis: depletion of IgE does not improve the clinical course—a randomized,
placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010;8:
990-8.
115. Holm JG, Agner T, Sand C, Thomsen SF. Omalizumab for atopic dermatitis: case
series and a systematic review of the literature. Int J Dermatol 2017;56:18-26.
116. Uysal P, Birtekocak F, Karul AB. The relationship between serum TARC, TSLP
and POSTN levels and childhood atopic dermatitis. Clin Lab 2017;63:1071-7.
117. Sung M, Lee KS, Ha EG, Lee SJ, Kim MA, Lee SW, et al. An association of peri-
ostin levels with the severity and chronicity of atopic dermatitis in children. Pe-
diatr Allergy Immunol 2017;28:543-50.
118. Raap U, Wichmann K, Bruder M, Stander S, Wedi B, Kapp A, et al. Correlation
of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol
2008;122:421-3.
119. Ozceker D, Bulut M, Ozbay AC, Dilek F, Koser M, Tamay Z, et al. Assessment of
IL-31 levels and disease severity in children with atopic dermatitis. Allergol Im-
munopathol (Madr) 2018;46:322-5.
120. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, et al. Enhanced
expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic
contact dermatitis. J Allergy Clin Immunol 2006;118:930-7.
121. Nygaard U, Hvid M, Johansen C, Buchner M, Folster-Holst R, Deleuran M, et al.
TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of
adult and childhood atopic dermatitis. J Eur Acad Dermatol Venereol 2016;30:
1930-8.
122. Miyahara H, Okazaki N, Nagakura T, Korematsu S, Izumi T. Elevated umbilical
cord serum TARC/CCL17 levels predict the development of atopic dermatitis in
infancy. Clin Exp Allergy 2011;41:186-91.
123. Wen HJ, Wang YJ, Lin YC, Chang CC, Shieh CC, Lung FW, et al. Prediction of
atopic dermatitis in 2-yr-old children by cord blood IgE, genetic polymorphisms
in cytokine genes, and maternal mentality during pregnancy. Pediatr Allergy Im-
munol 2011;22:695-703.
124. Ni Chaoimh C, Nico C, Puppels GJ, Caspers PJ, Wong X, Common JE, et al.
In vivo Raman spectroscopy discriminates between FLG loss-of-function
carriers vs wild-type in day 1-4 neonates. Ann Allergy Asthma Immunol 2020;
124:500-4.
125. Kelleher M, Dunn-Galvin A, Hourihane JO, Murray D, Campbell LE, McLean
WH, et al. Skin barrier dysfunction measured by transepidermal water loss at 2
days and 2 months predates and predicts atopic dermatitis at 1 year. J Allergy
Clin Immunol 2015;135:930-5.e1.
126. Horimukai K, Morita K, Narita M, Kondo M, Kabashima S, Inoue E, et al. Trans-
epidermal water loss measurement during infancy can predict the subsequent
development of atopic dermatitis regardless of filaggrin mutations. Allergol Int
2016;65:103-8.
127. Dominguez-Huttinger E, Christodoulides P, Miyauchi K, Irvine AD, Okada-Hata-
keyama M, Kubo M, et al. Mathematical modeling of atopic dermatitis reveals
‘‘double-switch’’ mechanisms underlying 4 common disease phenotypes.
J Allergy Clin Immunol 2017;139:1861-72.e7.
128. Glatz M, Jo JH, Kennedy EA, Polley EC, Segre JA, Simpson EL, et al. Emollient
use alters skin barrier and microbes in infants at risk for developing atopic derma-
titis. PLoS One 2018;13:e0192443.
129. Lauffer F, Baghin V, Standl M, Stark SP, Jargosch M, Wehrle J, et al. Predicting
persistence of atopic dermatitis in children using clinical attributes and serum pro-
teins [published online ahead of print August 13, 2020]. Allergy. https://doi.org/
10.1111/all.14557.
130. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D,
et al. Long-term management of moderate-to-severe atopic dermatitis with dupi-
lumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a
1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet
2017;389:2287-303.
131. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al.
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J
Med 2016;375:2335-48.
132. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Se-
cukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014;
371:326-38.
133. Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, et al. Baseline
IL22 expression in atopic dermatitis patients stratifies tissue responses to fezaki-
numab. J Allergy Clin Immunol 2019;143:142-54.
134. Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, et al. Efficacy
and safety of ustekinumab treatment in adults with moderate-to-severe atopic
dermatitis. Exp Dermatol 2017;26:28-35.
135. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II
placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Re-
spir J 2013;41:330-8.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
RENERT-YUVAL ET AL 17136. Emson C, Pham TH, Manetz S, Newbold P. Periostin and dipeptidyl peptidase-4:
potential biomarkers of interleukin 13 pathway activation in asthma and allergy.
Immunol Allergy Clin North Am 2018;38:611-28.
137. Glickman JW, Han J, Garcet S, Krueger JG, Pavel AB, Guttman-Yassky E.
Improving evaluation of drugs in atopic dermatitis by combining clinical and mo-
lecular measures. J Allergy Clin Immunol Pract 2020;8:3622-5.e19.
138. Roekevisch E, Szegedi K, Hack DP, Schram ME, Res P, Bos JD, et al. Effect of
immunosuppressive treatment on biomarkers in adult atopic dermatitis patients.
J Eur Acad Dermatol Venereol 2020;34:1545-54.
139. Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O. Molecular
cloning of a novel T cell-directed CC chemokine expressed in thymus by signal
sequence trap using Epstein-Barr virus vector. J Biol Chem 1996;271:21514-21.
140. Thyssen JP, Andersen YMF, Zhang H, Gislason G, Skov L, Egeberg A. Incidence
of pediatric atopic dermatitis following thymectomy: a Danish register study. Al-
lergy 2018;73:1741-3.
141. Olesen AB, Andersen G, Jeppesen DL, Benn CS, Juul S, Thestrup-Pedersen K.
Thymus is enlarged in children with current atopic dermatitis. A cross-sectional
study. Acta Derm Venereol 2005;85:240-3.
142. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG. A
Th2 chemokine, TARC, produced by keratinocytes may recruit CLA1CCR41
lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 2000;115:
640-6.
143. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial
and ethnic groups—variations in epidemiology, genetics, clinical presentation
and treatment. Exp Dermatol 2018;27:340-57.
144. Noda S, Suarez-Farinas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, et al. The
Asian atopic dermatitis phenotype combines features of atopic dermatitis and psori-
asis with increased TH17 polarization. J Allergy Clin Immunol 2015;136:1254-64.
145. Zheng X, Nakamura K, Furukawa H, Nishibu A, Takahashi M, Tojo M, et al.
Demonstration of TARC and CCR4 mRNA expression and distribution using in
situ RT-PCR in the lesional skin of atopic dermatitis. J Dermatol 2003;30:26-32.
146. Patel N, Feldman SR. Adherence in atopic dermatitis. Adv Exp Med Biol 2017;
1027:139-59.
147. Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17
and skin diseases. J Dermatol Sci 2006;43:75-84.
148. Murayama T, Nakamura K, Tsuchida T. Eosinophilic pustular folliculitis with
extensive distribution: correlation of serum TARC levels and peripheral blood
eosinophil numbers. Int J Dermatol 2015;54:1071-4.
149. Motegi S, Hattori M, Shimizu A, Abe M, Ishikawa O. Elevated serum levels of
TARC/CCL17, eotaxin-3/CCL26 and VEGF in a patient with Kimura’s disease
and prurigo-like eruption. Acta Derm Venereol 2014;94:112-3.
150. Cuccaro A, Annunziata S, Cupelli E, Martini M, Calcagni ML, Rufini V, et al.
CD681 cell count, early evaluation with PET and plasma TARC levels predict
response in Hodgkin lymphoma. Cancer Med 2016;5:398-406.
151. Dallos T, Heiland GR, Strehl J, Karonitsch T, Gross WL, Moosig F, et al. CCL17/
thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis
Rheum 2010;62:3496-503.
152. Chan TC, Sanyal RD, Pavel AB, Glickman J, Zheng X, Xu H, et al. Atopic
dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform fea-
tures. J Allergy Clin Immunol 2018;142:1013-7.
153. Gupta J, Grube E, Ericksen MB, Stevenson MD, Lucky AW, Sheth AP, et al.
Intrinsically defective skin barrier function in children with atopic dermatitis cor-
relates with disease severity. J Allergy Clin Immunol 2008;121:725-30.e2.154. Leung DYM, Calatroni A, Zaramela LS, LeBeau PK, Dyjack N, Brar K, et al. The
nonlesional skin surface distinguishes atopic dermatitis with food allergy as a
unique endotype. Sci Transl Med 2019;11:eaav2685.
155. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and
allergic diseases. N Engl J Med 2011;365:1315-27.
156. Tham EH, Leung DY. Mechanisms by which atopic dermatitis predisposes to food
allergy and the atopic march. Allergy Asthma Immunol Res 2019;11:4-15.
157. Simpson EL, Villarreal M, Jepson B, Rafaels N, David G, Hanifin J, et al. Patients
with atopic dermatitis colonized with Staphylococcus aureus have a distinct
phenotype and endotype. J Invest Dermatol 2018;138:2224-33.
158. Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, et al. The oral Ja-
nus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and
improves associated systemic inflammation in patients with moderate-to-severe
atopic dermatitis: results from a randomized double-blind placebo-controlled
study. Br J Dermatol 2019;181:733-42.
159. Dyjack N, Goleva E, Rios C, Kim BE, Bin L, Taylor P, et al. Minimally invasive
skin tape strip RNA sequencing identifies novel characteristics of the type
2-high atopic dermatitis disease endotype. J Allergy Clin Immunol 2018;141:
1298-309.
160. Hulshof L, Hack DP, Hasnoe QCJ, Dontje B, Jakasa I, Riethmuller C, et al. A
minimally invasive tool to study immune response and skin barrier in children
with atopic dermatitis. Br J Dermatol 2019;180:621-30.
161. Engebretsen KA, Bandier J, Kezic S, Riethmuller C, Heegaard NHH, Carlsen BC,
et al. Concentration of filaggrin monomers, its metabolites and corneocyte surface
texture in individuals with a history of atopic dermatitis and controls. J Eur Acad
Dermatol Venereol 2018;32:796-804.
162. Clausen ML, Slotved HC, Krogfelt KA, Agner T. Measurements of AMPs in stra-
tum corneum of atopic dermatitis and healthy skin-tape stripping technique. Sci
Rep 2018;8:1666.
163. Berdyshev E, Goleva E, Bronova I, Dyjack N, Rios C, Jung J, et al. Lipid ab-
normalities in atopic skin are driven by type 2 cytokines. JCI Insight 2018;3:
e98006.
164. Kim BE, Goleva E, Kim PS, Norquest K, Bronchick C, Taylor P, et al. Side-by-
side comparison of skin biopsies and skin tape stripping highlights abnormal stra-
tum corneum in atopic dermatitis. J Invest Dermatol 2019;139:2387-9.e1.
165. Aronson JK, Ferner RE. Biomarkers—a general review. Curr Protoc Pharmacol
2017;76:9.23.1-9.23.17.
166. Brunner PM, Emerson RO, Tipton C, Garcet S, Khattri S, Coats I, et al. Nonle-
sional atopic dermatitis skin shares similar T-cell clones with lesional tissues. Al-
lergy 2017;72:2017-25.
167. Czarnowicki T, Malajian D, Shemer A, Fuentes-Duculan J, Gonzalez J,
Suarez-Farinas M, et al. Skin-homing and systemic T-cell subsets show higher
activation in atopic dermatitis versus psoriasis. J Allergy Clin Immunol 2015;
136:208-11.
168. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endo-
types and implications for targeted therapeutics. J Allergy Clin Immunol 2019;
143:1-11.
169. Berin MC. The role of TARC in the pathogenesis of allergic asthma. Drug News
Perspect 2002;15:10-6.
170. Takeuchi H, Yamamoto Y, Kitano H, Enomoto T. Changes in thymus- and
activation-regulated chemokine (TARC) associated with allergen immunotherapy
in patients with perennial allergic rhinitis. J Investig Allergol Clin Immunol 2005;
15:172-6.
IEC SURVEY ON BIOMARKERS IN AD




d Which are you using?
o IgE
o Eosinophils
o Other (please specify)
d Do you think that blood tests/biomarkers are useful for as-
sessing the severity of AD?
o No
o Yes
d If no, why?
d If yes, why?
o Improve selection of patients for therapy or trials
improve the comparability of trials
o For follow-up in daily practice
o Other (please specify)







o sIL-2R (soluble IL-2 receptor)
o IL-22/IL-13/p-EASI (CCL17/IL-22/sIL-2R)
o Other (please specify)





d Which biomarkers would you suggest?
d Do you think that AD is a heterogeneous disease?
o No
o Yes






d How would you proceed to stratify the heterogeneous
phenotype?
o Only by clinical features
o Only by biomarkers
o Combining clinical features and biomarkers
d What clinical features would you suggest?
d Which biomarkers would you suggest?
o Genetics
o Genomics/transcriptomics in skin biopsies
o Soluble markers/proteomics in blood samples
o Tape-strip proteomic analyses
o Tape-strip genomic/transcriptomic analyses
o TEWL
o Other biomarker analyses





o Other (please specify)
d Which clinical features would you suggest?
d Which groups of biomarkers would you suggest?
o Genomics/transcriptomics in skin
o Genomics/transcriptomics in tape-strips
o Soluble markers/proteomics in skin
o Soluble markers in blood
o Proteomics in tape-strips
o Physiological properties (eg, TEWL and Raman)
o Other (please specify)




o Other (please specify)
d How would you prioritize the needs for blood test/bio-
markers? (1 is the highest priority and 10 is the lowest)
Better biomarkers for diseases severity 1 2 3 4 5 6 7 8 9 10
Better diagnostic biomarkers (eg, in adult-onset AD) 1 2 3 4 5 6 7 8 9 10
Less-invasive biomarkers (eg, skin strips) for use in infants (or ‘‘field studies’’) 1 2 3 4 5 6 7 8 9 10
Better biomarkers for prediction of treatment response 1 2 3 4 5 6 7 8 9 10
Better biomarkers as readout of treatment response (eg, to enable comparison of the effectiveness of different
treatments)
1 2 3 4 5 6 7 8 9 10
Better biomarkers for identification of endo(pheno) types to predict treatment response to systemic treatment/biologics 1 2 3 4 5 6 7 8 9 10
Biomarkers that will be able to identify responders to a particular drug before initiation of treatment 1 2 3 4 5 6 7 8 9 10
Biomarkers that will stratify responders and nonresponders in clinical trials 1 2 3 4 5 6 7 8 9 10
Biomarkers to predict the natural course of the disease (eg, in infants) 1 2 3 4 5 6 7 8 9 10
Biomarkers to predict the disease development/determine persons at risk to develop AD (in infants) 1 2 3 4 5 6 7 8 9 10
EASI, Eczema Area and Severity Index; LDH, lactate dehydrogenase; TEWL, transepidermal water loss.
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